Loading
companiesCompany
Hutchmed
Hutchmed discovered fruquintinib, the first Chinese cancer drug approved by the FDA for a common cancer, and savolitinib, its MET inhibitor partnered with AstraZeneca.
Also called: HUTCHMED (China)Hutchison China MediTechChi-Med和黄医药Hutchison MedipharmaHUTCHMED
Overview
Shanghai discovery engine with three NMPA-approved originals: fruquintinib (colorectal 2018; FDA approval November 2023 after Takeda licensed ex-China rights for $400 million upfront), surufatinib (neuroendocrine tumours 2020) and savolitinib (MET exon 14 NSCLC 2021, with AstraZeneca). Also sovleplenib (Syk) and tazemetostat rights in China. Its FDA approval of fruquintinib in a global population (FRESCO-2) showed the route Chinese drugs must take: a multiregional confirmatory trial.
Headquarters
Hong Kong / Shanghai, CN
Scorecard
All companies#24of 1244 companies, score 97
- approved products +18
- phase 3 +12
- phase 1/2 +2
- targets +20
- modalities +8
- regions +7
- registry trials +30
3 approved, 4 in phase 3, 2 earlier, 10 targets, 287 registry studies. Formula on the scorecards page.
Deals
Deal mapType
Biotech · HCM / 13.HK
Stage
Public
Website
Founded
2000
ApprovedSmall-molecule kinase inhibitor (VEGFR1-3)
Fruquintinib · Fruzaqla
A Chinese-discovered pill that blocks the blood-vessel receptors, approved in 2023 for bowel cancer after all standard treatments.
ApprovedSmall-molecule selective MET TKI
Savolitinib · Orpathys
Savolitinib is a Chinese-discovered pill that blocks the MET growth signal, approved in China for lung cancers with a MET exon 14 mutation and being tested worldwide with osimertinib.
ApprovedOral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor
Surufatinib is HUTCHMED's angio-immuno kinase inhibitor, approved in China in 2020 for non-pancreatic and in 2021 for pancreatic neuroendocrine tumours.
Phase 3small molecule
HMPL-306 is an experimental small-molecule drug from Hutchmed in phase 3 trials for acute myeloid leukaemia, aimed at IDH1 / IDH2.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
HMPL-453 is an experimental small-molecule drug from Hutchmed in phase 3 trials for biliary tract cancer, aimed at FGFR2.
Phase 3small molecule (structure undisclosed or not yet in PubChem)
HMPL-760 is an experimental small-molecule drug from Hutchmed in phase 3 trials for diffuse large B-cell lymphoma, with its target not yet stated publicly.
Phase 3monoclonal antibody (anti-HER2, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)
IAH0968 is an experimental small-molecule drug from SUNHO（China）BioPharmaceutical CO. in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at HER2.
Phase 2bispecific antibody
LB1410 is an experimental bispecific antibody from L & L Bio, Ningbo, China in phase 2 trials, aimed at PD-1 and TIM-3.
Phase 2fusion protein
LB4330 is an experimental fusion protein from L & L Bio, Ningbo, China in phase 2 trials, aimed at Claudin 18.2.
Samantha Du (Du Ying)
Founder, Chairperson and CEO, Zai Lab
In-licensingBiotech leadershipOncology commercialisation
Samantha Du founded Zai Lab in 2014 to license Western cancer drugs for China, bringing niraparib, zanidatamab and Tumour Treating Fields to Chinese patients years earlier than they would otherwise have arrived.
Weiguo Su
CEO and Chief Scientific Officer, Hutchmed
Kinase inhibitor discoveryMedicinal chemistry
Weiguo Su led the Shanghai chemistry that produced fruquintinib, savolitinib and surufatinib, three Chinese-discovered cancer pills approved at home and, for fruquintinib, in the US.
Similar pages
- CompanyZai Lab
Shares Samantha Du (Du Ying) and the tag china.
- TreatmentSintilimab
Shares Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer and the tag china.
- CompanyInnovent Biologics
Shares Takeda and the tag china.
- CompanyCSPC Pharmaceutical Group
Shares AstraZeneca and the tag china.
- TrialA Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
- CompanySunHo Biopharmaceutical
Shares IAH0968, To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer.
fronts
drugs
ApprovedSmall-molecule kinase inhibitor (VEGFR1-3)
Fruquintinib · Fruzaqla
Phase 3small molecule
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3small molecule (structure undisclosed or not yet in PubChem)
Phase 3monoclonal antibody (anti-HER2, per the sponsor's pipeline page; registered as a drug on ClinicalTrials.gov)
Phase 2bispecific antibody
Phase 2fusion protein
ApprovedSmall-molecule selective MET TKI
Savolitinib · Orpathys
ApprovedOral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor
companies
trials
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid TumorsA Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLA Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid LeukemiaClinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLCFRESCOFRESCO-2HMPL-453 Tartrate in Advanced Intrahepatic CholangiocarcinomaHMPL-A580 in Participants With Advanced or Metastatic Solid TumorOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibSANET-ep and SANET-pSavolitinib vs. Sunitinib in MET-driven PRCC.Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial CancerStudy of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCLTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer